Article
Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop.
Hematology. American Society of Hematology. Education Program - 4 Dec 2020
Wang Eunice S, Baron Jeffrey
Abstract excerpt
The recent advent of myriad targeted therapies for acute myeloid leukemia (AML) has led to new hope for our patients but has also introduced new challenges in managing the disease. For clinicians, the ability to treat AML in the outpatient setting with novel agents of equal or greater efficacy than 7+3 has been transformative. Despite the enthusiasm, however, the reality is that many patients are still frail and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.